Results 231 to 240 of about 950,400 (402)
Cytogenetic events after bone marrow transplantation for chronic myeloid leukemia in chronic phase [PDF]
CK Arthur+5 more
openalex +1 more source
Expert Perspective: Hematologic Malignancies and Vasculitis
Arthritis &Rheumatology, EarlyView.
Michelle L. Robinette, Hetty E. Carraway
wiley +1 more source
Abstract A modified controlled‐release sodium valproate formulation (VAL001, test) was compared with an approved enteric‐coated tablet formulation (Absenor, reference). Pharmacokinetics and safety/tolerability were evaluated in healthy subjects to bridge with positive efficacy results from an early‐phase patient trial of valproate in combination with ...
Nikhil Ahuja+8 more
wiley +1 more source
Acute myeloid leukemia complicated with tuberculosis.
Keiko Morikawa, Yoko Niki, H Hoshizaki
openalex +2 more sources
In vitro action of tumor necrosis factor on myeloid leukemia cells [PDF]
Reinhold Munker, P Koeffler
openalex +1 more source
Pharmacomicrobiomics is an emerging field due to important microbiome effects on pharmacokinetics and clinical outcomes. However, the application of this knowledge remains limited. Mycophenolic acid (MPA) is the primary active metabolite of the immunosuppressant, mycophenolate mofetil (MMF).
Abdelrahman Saqr+4 more
wiley +1 more source
AKI in chronic myeloid leukemia: remember lysozyme-induced nephropathy. [PDF]
Santos A, Marques N, Pestana R.
europepmc +1 more source
c-fms expression is a molecular marker of human acute myeloid leukemias [PDF]
Patrice Dubreuil+4 more
openalex +1 more source
ABSTRACT Suspension and imaging mass cytometry are single‐cell, proteomic‐based methods used to characterize tissue composition and structure. Data assessing the consistency of these methods over an extended period of time are still sparse and are needed if mass cytometry‐based methods are to be used clinically.
Ruben Casanova+141 more
wiley +1 more source